



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Manel Puig Domingo**

Organisation/Company: European Society of Endocrinology (ESE)

Country: Spain

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/2017-(current)	Lilly	Dulaglutide, nasal glucagon	Diabetes
01/2018-(current)	Sanofi	Alirocumab	Hypercholesterolemia
07/2020-07/2020	RECORDATI	Pasireotide	Acromegaly
01/2021-01/2021	RECORDATI	Pasireotide	Acromegaly

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
07/2020-07/2020	RECORDATI	Advisor; acromegaly	

2.4 Financial interests

Company	Financial Interest
---------	--------------------

Classified as public by the European Medicines Agency

2

Kintsugy Therapeutics (start up company)	owner of 0.5% of stock options
--	--------------------------------

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2017-12/2018	Chiasma	oral octreotide	acromegaly
01/2018-05/2019	GSK	GSK256063	diabetes mellitus

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Pfizer	Early diagnosis of acromegaly through facial recognition computer-based tools

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

Member of European Society of Endocrinology to the HCPWP, their funding details can be found here:
<https://www.es-e-hormones.org/about-us/how-es-e-is-funded/>

- Acromegaly personalised treatment trial; grant from Instituto Carlos III; Spanish ministry of Science (2016-2019) (PI Manuel Puig-Domingo)
- Past-Director of Germans Trias Research Institute, Badalona, Spain
- Past-President of the Spanish Society of Endocrinology Society (2017-2020)
- As Head of Endocrinology Service at Germans Trias University Hospital, our institution is receiving regularly funding for organization of independent academic courses related to diabetes, obesity, thyroid diseases and neuroendocrine diseases, by unrestricted educational grants from: NovoNordisk, AstraZeneca, Lilly, Sanofi, Ipsen, Novartis, MSD
- I have given lectures payed by the industry or in simposia supported by the industry, from: Sanofi, Novartis, NovoNordisk

2.11 CAT member or alternate

No interest declared

CONFIDENTIALITY UNDERTAKING

Classified as public by the European Medicines Agency

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Manuel Puig-Domingo
Date:	2021-02-02

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template